by Brian Shilhavy
Editor, Health Impact News
After injecting Americans with over 300 million doses of one of the mRNA COVID-19 bioweapon shots since December 13, 2020, the FDA has finally agreed to force Moderna and Pfizer to put warning labels on their shots over a “likely association” between the injections and heart problems, which they claim is “rare.”
The warning comes as the vast majority of Americans who wanted one of the mRNA injections have already been injected, as demand for the shots has decreased to levels seen back in December, just after the shots were given emergency use authorization and were beginning to be rolled out.
According to the CDC’s latest report published yesterday, June 23, 2021, “318 million doses of COVID-19 vaccines were administered in the United States from December 14, 2020, through June 21, 2021,” with only 12 million of those doses being the “J&J/Janssen COVID-19 Vaccine.”
As we have been reporting throughout the rollout of these non-FDA approved injections, hundreds of cases of people suffering heart problems, including DEATH, have been reported to VAERS, the Government database that tracts adverse reactions to “vaccines.”
The pharmaceutical trade publication, FiercePharma, which views vaccines from strictly a business investment viewpoint, reports:
Numerous COVID-19 vaccines have faced development delays and safety and supply issues, but the mRNA vaccines from Pfizer-BioNTech and Moderna have enjoyed a relatively unfettered ride to the top of the class.
Now, Wednesday’s news that U.S. experts concluded there is a “likely association” between rare cases of heart inflammation and mRNA vaccines has finally presented the Pfizer-BioNTech and Moderna shots with a dose of adversity. The FDA said it will move quickly to require the companies to add a label warning that young adults and adolescents are susceptible to the side effect.
While the Centers for Disease Control and Prevention (CDC) concluded that the benefits of the vaccine clearly outweigh risks, the verdict could compel those with apprehension to favor adenovirus-type vaccines offered by Johnson & Johnson and AstraZeneca.
Those shots faced safety concerns of their own earlier this year over rare but severe cases of blood clots, which led to fatalities. After an investigation, J&J’s vaccine now carries a warning in the U.S.